Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma

Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma

Abstract Background There is increasing interest in enhancing the response of the PARP inhibitor olaparib, which is currently approved for pancreatic ductal adenocarcinoma (PDAC) patients with defects in DNA damage repair associated with germline BRCA1/2 mutations. Moreover, agents that can mimic th...

Full description

Saved in:
Bibliographic Details
Main Authors: Thao D. Pham, Jeffrey H. Becker, Anastasia E. Metropulos, Nida Mubin, Christina Spaulding, David J. Bentrem, Hidayatullah G. Munshi
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Cancer
Subjects:
Pancreatic cancer
Regorafenib
DNA damage
Rad51
Olaparib
Syngeneic mouse model
Online Access:https://doi.org/10.1186/s12885-024-13334-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items